Structure Therapeutics Inc. (GPCR)
After hours:
| Previous close | 38.65 |
| Open | 36.79 |
| Bid | 35.68 x 100 |
| Ask | 35.95 x 100 |
| Day's range | 35.77 - 39.10 |
| 52-week range | 21.79 - 75.02 |
| Volume | |
| Avg. volume | 585,655 |
| Market cap | 1.67B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.43 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 80.50 |
GlobeNewswireStructure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
Topline GSBR-1290 Phase 2a 12-week obesity data on track for June 2024 Phase 2b study in obesity expected to begin as planned in the fourth quarter 2024 Plan to initiate dosing in first-in-human Phase 1 clinical trial of oral small molecule LPA1R Antagonist, LTSE-2578, for idiopathic pulmonary fibrosis in June 2024 SAN FRANCISCO, May 09, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule ther
Simply Wall St.We Think Structure Therapeutics (NASDAQ:GPCR) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- GlobeNewswire
Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference
SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that Raymond Stevens, Ph.D., the Company’s Founder and Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Wednesday, March 13, 2024, at 8:00 AM ET in Miami, Florida. The live and ar
